Targeting CCR7-PI3Ky overcomes resistance to tyrosine kinase inhibitors AKL-rearranged lymphoma – Marco Campisi

I am happy to share that one of my collaborative efforts is finally out in Science Translational Medicine! A great work from the Chiarle lab at Università degli Studi di Torino and Boston Children’s Hospital.

Blockade of PI3Kγ and CCR7 signaling combined with ALK tyrosine kinase inhibitors treatment reduces primary resistance and survival of persister anaplastic large cell lymphoma.

Big thanks to all the authors, in particular to Claudia Voena and Roberto Chiarle who led this work!

For details: Click here

Source: Marco Campisi/linkedin